ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva < sup > ® < /sup > ) alone

ATS 2014 COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva < sup > ® < /sup > ) alone
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news